| Popis: |
Dysregulated type I interferon responses play crucial roles in the development of multiple forms of autoimmunity. Many patients with lupus, systemic sclerosis, Sjogren’s syndrome, and dermatomyositis demonstrate enhanced type I IFN signaling. Type I IFN excess is associated with disease severity, autoantibodies, and could potentially predict response to newer therapies targeting type I IFN pathways. Herein, we provide an overview of the signaling pathway and immune functions of type I IFNs in health and disease. We also review the systemic autoimmune diseases classically associated with type I IFN upregulation and current therapeutic strategies targeting the type I IFN system. |
